Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| LCTX | Lineage Cell Therapeutics, Inc. | 2026-10-15 14:33:48 | 0.99 | 0.07 | 7.66 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LCTX | 0000876343 | Lineage Cell Therapeutics, Inc. | US53566P1093 | — | 943127919 | NYSE | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | CA | 2173 SALK AVENUE | CARLSBAD | CA | 92008 | UNITED STATES | US | 5105213390 | 2173 SALK AVENUE, CARLSBAD, CA, 92008 | 2173 SALK AVENUE, CARLSBAD, CA, 92008 | BIOTIME INC | Biotechnology | 1990 | — | — | https://lineagecell.com/ | 161,500,000 | 252,907,464 | 252,907,464 | Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. | 2026-10-09 04:08:29 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 161,500,000 | 15,200,000 | 10.3896 | 249,087,529 | 20,731,239 | 9.0785 |
| 2024 | 146,300,000 | -39,300,000 | -21.1746 | 228,356,290 | 39,822,754 | 21.1224 |
| 2023 | 185,600,000 | -15,000,000 | -7.4776 | 188,533,536 | 18,359,747 | 10.7888 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Chase C. Leavitt | General Counsel, Corporate Secretary | 2020 | 346,300 | 131,600 | — | — | 14,250 | 752,952 |
| Brandi L. Roberts | Chief Financial Officer | 2020 | 393,200 | 0 | — | — | 14,250 | 668,252 |
| Brian M. Culley | Chief Executive Officer, Chief Financial Officer | 2020 | 551,900 | 262,200 | — | — | 14,250 | 1,349,913 |
| Chase C. Leavitt | General Counsel, Corporate Secretary | 2019 | 210,146 | 102,100 | 0 | — | 9,542 | 599,098 |
| Brandi L. Roberts | Chief Financial Officer | 2019 | 376,137 | 169,900 | 0 | — | 3,978 | 947,963 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 77 |
| 2024 | 77 |
| 2023 | 75 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 14,556,000 | 9,499,000 | 8,945,000 |
| Cost Of Revenue | — | 334,000 | 671,000 |
| Gross Profit | 14,556,000 | 9,165,000 | 8,274,000 |
| Research And Development Expenses | 17,729,000 | 12,472,000 | 15,705,000 |
| General And Administrative Expenses | 18,460,000 | 18,171,000 | 17,302,000 |
| Operating Expenses | 51,175,000 | 30,977,000 | 33,007,000 |
| Operating Income | -36,619,000 | -21,478,000 | -24,733,000 |
| Net Income | -63,533,000 | -18,609,000 | -21,486,000 |
| Earnings Per Share Basic | -0.28 | -0.09 | -0.12 |
| Earnings Per Share Diluted | -0.28 | -0.09 | -0.12 |
| Weighted Average Shares Outstanding Basic | 230,116,000 | 200,193,000 | 172,663,000 |
| Weighted Average Shares Outstanding Diluted | 230,116,000 | 200,193,000 | 172,663,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 40,791,000 | 45,789,000 | 35,442,000 |
| Marketable Securities Current | 14,990,000 | 2,016,000 | 50,000 |
| Accounts Receivable | 891,000 | 638,000 | 745,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 2,485,000 | 2,554,000 | 2,204,000 |
| Total Assets Current | 59,157,000 | 50,997,000 | 38,441,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 2,566,000 | 2,251,000 | 4,767,000 |
| Other Assets Non Current | 31,700,000 | 46,540,000 | — |
| Total Assets Non Current | 53,427,000 | 62,221,000 | 62,578,000 |
| Total Assets | 112,584,000 | 113,218,000 | 101,019,000 |
| Accounts Payable | 2,341,000 | 1,174,000 | 2,050,000 |
| Deferred Revenue | 3,333,000 | 7,388,000 | 10,808,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 1,096,000 | 1,197,000 | 1,097,000 |
| Total Liabilities Current | 11,367,000 | 13,977,000 | 17,960,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | 0 |
| Total Liabilities Non Current | 57,871,000 | 22,229,000 | 21,036,000 |
| Total Liabilities | 69,238,000 | 36,206,000 | 38,996,000 |
| Common Stock | 515,467,000 | 484,722,000 | 451,343,000 |
| Retained Earnings | -466,998,000 | -403,465,000 | -384,856,000 |
| Accumulated Other Comprehensive Income | -3,920,000 | -2,876,000 | -3,068,000 |
| Total Shareholders Equity | 44,549,000 | 78,381,000 | 63,419,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 699,000 | 587,000 | 562,000 |
| Share Based Compensation Expense | 4,752,000 | 5,077,000 | 4,640,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 316,000 | -106,000 | 446,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -46,000 | -489,000 | 418,000 |
| Change In Accounts Payable | 2,271,000 | -1,681,000 | -2,295,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -18,919,000 | -23,092,000 | -28,566,000 |
| Purchases Of Marketable Securities | 14,935,000 | 8,761,000 | 16,403,000 |
| Sales Of Marketable Securities | 0 | 18,000 | 196,000 |
| Acquisition Of Property Plant And Equipment | 522,000 | 565,000 | 674,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -13,457,000 | -2,308,000 | 46,449,000 |
| Tax Withholding For Share Based Compensation | 16,000 | 23,000 | 37,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 1,250,000 | 229,000 | 6,625,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 26,950,000 | 35,857,000 | 6,423,000 |
| Change In Cash | -5,030,000 | 10,362,000 | 24,056,000 |
| Cash At End Of Period | 40,791,000 | 45,789,000 | 35,442,000 |
| Income Taxes Paid | 0 | — | — |
| Interest Paid | 29,000 | 9,000 | 10,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.28 | -0.09 | -0.12 |
| Price To Earnings Ratio | -5.9643 | -5.5833 | -9.0833 |
| Earnings Growth Rate | 211.1111 | -25 | -20 |
| Price Earnings To Growth Ratio | -0.0283 | 0.2233 | 0.4542 |
| Book Value Per Share | 0.1884 | 0.3847 | 0.3592 |
| Price To Book Ratio | 8.8657 | 1.3063 | 3.0344 |
| Ebitda | -62,834,000 | -18,022,000 | -20,924,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 1,014,000 | -1,929,000 | -344,000 |
| Free Cash Flow | -19,933,000 | -21,163,000 | -28,222,000 |
| Return On Equity | -1.4261 | -0.2374 | -0.3388 |
| One Year Beta | 0.9964 | 1.4642 | 0.8898 |
| Three Year Beta | 1.0669 | 1.0841 | 1.1854 |
| Five Year Beta | 1.1643 | 1.2356 | 1.2392 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Bradsher Neal C | Director, 10% owner | 2026-07-01 | 125,000 | A | 125,000 |
| Amin Dipti | Director | 2026-07-01 | 125,000 | A | 125,000 |
| Russell Angus C. | Director | 2026-07-01 | 125,000 | A | 125,000 |
| ANDREWS DEBORAH J | Director | 2026-07-01 | 125,000 | A | 125,000 |
| Mulroy Michael H. | Director | 2026-07-01 | 125,000 | A | 125,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| WOLFF WIESE MAGANA LLC | 2026-09-30 | 956 | 1,000 | 0.956 |
| RED CRANE WEALTH MANAGEMENT, LLC | 2026-09-30 | 484,024 | 506,460 | 0.9557 |
| Connecticut Wealth Management, LLC | 2026-09-30 | 82,428 | 86,249 | 0.9557 |
| Founders Capital Management | 2026-09-30 | 15,291 | 16,000 | 0.9557 |
| ANCHYRA PARTNERS LLC | 2026-09-30 | 14,470 | 15,141 | 0.9557 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 21,668 | 23,401.44 | 0.0029 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 88,027 | 95,069.16 | 0.0064 |
| PRINCIPAL FUNDS, INC. | 2026-07-31 | R-6 | PCSMX | 14,103 | 15,231.24 | 0.0006 |
| PRINCIPAL FUNDS, INC. | 2026-07-31 | Class J | PSIJX | 14,103 | 15,231.24 | 0.0006 |
| PRINCIPAL FUNDS, INC. | 2026-07-31 | Institutional Class | PGRTX | 14,103 | 15,231.24 | 0.0006 |